Effect of diabetan on blood glucose, glycosylated hemoglobin, lipid profile, liver and kidney function tests of diabetic patients: A clinical, double blind, randomized trial

Considering the side effects of insulin and oral hypoglycemic agents, this study was performed with the aim of investigating the hypoglycemic effect of Diabetan (glycogol) tablet, which is a blend of Saliva officinalis, Trigonella foenum and ginseng. A double-blind clinical trial was carried out on type-2 diabetic patients who were referred to the Endocrine and Metabolism Clinic of Shahrekord University of Medical Sciences. Eighty type 2 diabetic patients who had not reached the ideal control of the disease were randomly divided into case and control groups. The case group received Diabetan and the control group received placebo tablets three times a day for three months. Glycosylated hemoglobin (HbA1c), lipid profile, liver and kidney function tests were carried out at the beginning and at the end of the trial. The fasting blood sugar (FBS) and 2 h postprandial (2hpp) glucose were also checked at the beginning and every 2 weeks, for three months and were compared in two mentioned groups. The 2hpp blood sugar and cholesterol levels decreased significantly in Diabetan treated patients as compared to the control group (P<0.05). There were no significant changes in glycosylated hemoglobin and FBS between the two groups. Results showed that Diabetan tablets might be beneficial in diabetic patients to reduce 2hpp and cholesterol. However, higher doses might be needed to decrease fasting blood glucose and glycosylated hemoglobin.